Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications
Plamotamab (XmAb®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia.
Journal: Leukemia & lymphoma
Published: November 16, 2021
Improved therapeutic efficacy of unmodified anti-tumor antibodies by immune checkpoint blockade and kinase targeted therapy in mouse models of melanoma.
Journal: Oncotarget
Published: August 14, 2020
An open-label study evaluating the efficacy of abatacept in alopecia areata.
Journal: Journal of the American Academy of Dermatology
Published: June 14, 2020
Redirected T Cell Cytotoxicity in Cancer Therapy.
Journal: Annual review of medicine
Published: November 01, 2018
Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer.
Journal: Breast cancer research : BCR
Published: December 07, 2017
An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Journal: The Journal of investigative dermatology
Published: September 19, 2017
Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.
Journal: JCI insight
Published: October 05, 2016
Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
Journal: Experimental dermatology
Published: April 21, 2016
Molecular signatures define alopecia areata subtypes and transcriptional biomarkers.
Journal: EBioMedicine
Published: February 01, 2016
Last Updated: 09/26/2026